Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ZS Pharma, Inc. | d869150dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 10, 2015 (February 4, 2015)
ZS Pharma, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36489 | 26-3305698 | ||
| (State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 508 Wrangler Drive, Suite 100 Coppell, Texas |
75019 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (877) 700-0240
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 4, 2015, Alvaro Guillem submitted notice of his resignation as a director of ZS Pharma, Inc. (the “Company”), effective immediately. Dr. Guillem did not resign due to any disagreement with the Company’s operations, policies or practices. Dr. Guillem shall continue to serve as President of the Company
On February 4, 2015, Martin Babler was appointed as a Class I independent director on the board of directors of the Company.
Mr. Babler was not elected pursuant to any arrangement or understanding with the Company or any affiliate of the Company. Mr. Babler will receive compensation for his service as a director in accordance with the Company’s non-employee director compensation policy, which is described in the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 18, 2014. The Company entered into an indemnification agreement with Mr. Babler, effective as of February 4, 2015, pursuant to which the Company agreed to indemnify Mr. Babler for certain claims and liabilities arising from Mr. Babler’s actions as a director of the Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number |
Description | |
| 99.1 | Press Release, dated February 10, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZS PHARMA, INC. | ||||||
| Date: February 10, 2015 | By: | /s/ Todd Creech | ||||
| Todd Creech | ||||||
| Chief Financial Officer | ||||||